Celltrion Expands Supply of Remsima and CT-P16

Incheon Songdo Celltrion Plant 2 Overview. / Incheon - Photo by Hyunmin Kim kimhyun81@

[Asia Economy Reporter Lee Chun-hee] Celltrion announced on the 24th that it has signed a supply contract worth 160.05747 billion KRW with Celltrion Healthcare for its autoimmune disease treatment biosimilar 'Remsima Intravenous Injection (IV)', non-small cell lung cancer and metastatic colorectal cancer treatment biosimilar 'CT-P16', and breast cancer and gastric cancer treatment biosimilar 'Herzuma'.

This contract aims to expand the supply of Remsima (sold as 'Inflectra' in the U.S.), which is increasing its market share in the United States, and to enable rapid global supply of CT-P16, which is pursuing approval within the year. Celltrion added that it plans to sign additional supply contracts within the second quarter following this agreement.

Remsima, Celltrion's flagship biosimilar, continues to show steady growth in the U.S., the world's largest biopharmaceutical market. While the market share of the original drug (Remicade) is declining, Remsima has steadily increased its share since 2020 by successfully being listed by major U.S. private insurers. According to market research firm Symphony Health data, Remsima's market share in the U.S. last month was 29.4%, showing a 6.8 percentage point increase so far this year.

Celltrion's biosimilar for autoimmune disease treatment, 'Remsima Subcutaneous Injection (SC)'.

In addition, Celltrion is also promoting the entry of Remsima Subcutaneous Injection (SC) into the U.S. market alongside Remsima IV. Remsima SC has already been launched in Europe, where it has shown a steep quarterly average growth rate of 42% over the past year. Clinical Phase 3 trials for Remsima SC are underway with the goal of commercializing it in the U.S. market next year.

CT-P16 also applied for marketing approval last year with the Korean Ministry of Food and Drug Safety, the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA), and is pursuing approval within the year. Furthermore, Celltrion has completed a global patent agreement with Genentech, the developer of the original drug 'Avastin', ensuring thorough preparation for global supply.

A Celltrion official stated, “With the expansion of supply of our core biosimilar business, we expect both sales and operating profit to grow in the second quarter compared to the first quarter. We will accelerate the approval and launch of new products following the strengthening of market share of existing products to secure future growth engines and establish a foundation for sustainable growth.”

This content was produced with the assistance of AI translation services.